Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$79.53 USD

79.53
3,306,185

-2.28 (-2.79%)

Updated Aug 5, 2024 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today

by Zacks Equity Research

Astrazeneca (AZN) concluded the recent trading session at $67.42, signifying a +0.81% move from its prior day's close.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates

by Kinjel Shah

Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.

Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?

by Zacks Equity Research

Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

Astrazeneca (AZN) concluded the recent trading session at $66.62, signifying a +0.54% move from its prior day's close.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

by Zacks Equity Research

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study

by Zacks Equity Research

J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.

AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong

by Zacks Equity Research

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.

Shaun Pruitt headshot

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

by Shaun Pruitt

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.

Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs

by Zacks Equity Research

Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed at $67.94 in the latest trading session, marking a -0.41% move from the prior day.

Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%

by Zacks Equity Research

Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

by Zacks Equity Research

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

by Zacks Equity Research

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

by Zacks Equity Research

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca

by Zacks Equity Research

Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications

by Kinjel Shah

The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.

Astrazeneca (AZN) Stock Moves -1.38%: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed at $67.02 in the latest trading session, marking a -1.38% move from the prior day.

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

by Zacks Equity Research

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed at $68.27 in the latest trading session, marking a +0.72% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More

by Kinjel Shah

The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.

Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo

by Zacks Equity Research

Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.